Evidence map›Paper›PMID 32441484›Full record

ArticleCancer medicine2020

Identification of the key genes associated with chemotherapy sensitivity in ovarian cancer patients.

Hui Zheng, Meiqin Zhang, Shuang Ma, Wenting Yang, Suhong Xie, Yanchun Wang, Yixuan Liu, Jinyan Kai, Qian Ma, Renquan Lu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Hui ZhengDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Meiqin ZhangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Shuang MaGenenexus Technology Corporation, Shanghai, China.ORCID 0000-0001-8776-7375
Wenting YangGenenexus Technology Corporation, Shanghai, China.
Suhong XieDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Yanchun WangDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Yixuan LiuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Jinyan KaiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Qian MaDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Renquan LuDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0003-3564-5979
Lin GuoDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Shanghai Medical College of Fudan University · CNFudan University Shanghai Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian cancer (OC) is the deadliest gynecological cancer. The absence of biomarkers in early detection and chemotherapy resistance is a principal cause of treatment failure in OC.

methodsIn this study, next generation sequencing (NGS) was used to sequence the mRNA of 44 OC patients including 14 chemotherapy insensitive and 18 sensitive patients. Differentially expressed genes (DEGs) from OC patients (compared with healthy controls) and chemotherapy sensitive patients (compared with chemotherapy insensitive patients) were identified by edgeR v3.12.0 in R v3.2.2, which were enriched using Gene Ontology (GO) database and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG). The common DEGs in cancer occurring and chemotherapy sensitivity were further screened. Among them, genes participating in chemotherapy sensitivity associated pathways were regarded as chemotherapy sensitivity-related key genes. Quantitative real-time PCR (qPCR) and immunohistochemistry (IHC) were used to verify the expression of the key genes.

resultsWe found 1588 DEGs between OC patients and healthy controls (HCs), which were mainly enriched in cell cycle pathway. Meanwhile, 249 DEGs were identified between chemotherapy sensitive and insensitive OC patients, which were mainly enriched in MAPK signaling pathway, ERBB signaling pathway, TNF signaling pathway, and IL-17 signaling pathway. Thirty-five DEGs were shared in chemotherapy sensitivity group and cancer occurring group. Among them, there are five genes (JUND, JUNB, MUC5B, NRG1, and NR4A1) participating in the above four chemotherapy sensitivity-related pathways. It is remarkable that JUND is in the upstream of MUC5B in IL-17 signaling pathway and their expressions were verified by qPCR and IHC.

conclusionsThe expression levels of the key genes related to chemotherapy sensitivity might be used as biomarkers to predict the treatment outcome and as a target to improve prognosis.

Indexed as

AdultAgedBiomarkers, TumorFemaleHigh-Throughput Nucleotide SequencingHumansMiddle AgedOvarian NeoplasmsBiomarkers, Tumorchemotherapy sensitivitykey genesNGSovarian cancerpathways

Identifiers

PMID32441484
PMCPMC7367617
OpenAlexW3028117519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.